GT Biopharma Financials - Benzinga

GT Biopharma Inc

GTBPNASDAQ

Trade with Public

Trade with Public

$0.2997

-0.0061-1.99%

At close: Aug 25, 5:00 PM EST

$0.2938

-0.0059-1.97%

After Hours: 5:57 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

GT Biopharma Financials

GT Biopharma (GTBP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
GT Biopharma Q2 EPS $(0.12) Misses $(0.08) Estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.08) by 50 percent. This is a 78.18 percent increase over losses of $(0.55) per share from the

Benzinga Newsdesk

PRO
GT Biopharma Q1 EPS $(0.11) Misses $(0.08) Estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 66.67 percent increase over losses of $(0.33) per share from the

Benzinga Newsdesk

PRO
GT Biopharma Q4 EPS $(4.84) Down From $(1.66) YoY

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(4.84) per share. This is a 191.57 percent decrease over losses of $(1.66) per share from the same period last year.

Benzinga Newsdesk

PRO
GT Biopharma Reported FY25 Net Loss Of $28.4M, Cash Balance Of ~$9M To Fund Operations Through The Fourth Quarter Of 2026

Year Ended December 31, 2025 Financial SummaryCash Position: The Company had cash and cash equivalents of approximately $7 million as of December 31, 2025, and an unaudited proforma cash balance as of January 31, 2026 of

Benzinga Newsdesk

PRO
GT Biopharma Q2 EPS $(0.55) Beats $(0.68) Estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.12 percent. This is a 74.65 percent increase over losses of $(2.17) per share from the

Benzinga Newsdesk

PRO
GT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) by 48.44 percent. This is a 79.88 percent increase over losses of $(1.64) per share from the

Benzinga Newsdesk